Diverse Clinical Manifestations of Cardiofaciocutaneous Syndrome Type 3 in Two Patients from South East Asia

Abstract

<b><i>Background:</i></b> Cardiofaciocutaneous syndrome (CFCS) is a rare genetic condition caused by mutations in <i>BRAF</i>, <i>KRAS</i>, <i>MAP2K1,</i> or <i>MAP2K2</i>. It is characterized by ectodermal abnormalities, cardiac defects, intellectual disability, and distinct craniofacial features. CFCS falls under a group of conditions caused by mutations in the RAS/MAPK pathway called RASopathies which share many features. In particular, CFCS has significant phenotypic overlaps with Costello syndrome (CS) and Noonan syndrome (NS). <b><i>Objective:</i></b> The aim of this study was to assess the patients’ phenotypic features for syndromic disorders and evaluate the use of molecular testing to clarify the clinical diagnosis. <b><i>Method:</i></b> The patients were recruited for genetic testing with written informed consent. Genomic DNA from venous blood was sequenced and potential variants were identified via targeted next-generation sequencing. Their phenotypic features were compared with other CFCS cases carrying pathogenic variants in the same gene. <b><i>Results and Discussion:</i></b> One patient had a de novo variant (c.370C&#x3e;T; p.P124S) in <i>MAP2K1</i> and presented with mild and typical features which do not significantly affect her quality of life. The second patient presented with severe features, including failure to thrive, feeding difficulties, epileptic spasms, septal hypertrophy, and global developmental delay, and developed chronic lung disease and sequelae from multiple infections. She had a severe disease course and severe global developmental delay. The discovery of a de novo variant (c.371C&#x3e;A; p.P124Q) in <i>MAP2K1,</i> which had been reported in another patient with a similar phenotype, clarifies her clinical diagnosis. Her presentations add to existing reports that support expanding the CFCS phenotype to include features previously thought to be more suggestive of CS. <b><i>Conclusion:</i></b> The genetic findings for the 2 patients affirm the use of identified gene mutations to confirm the clinical diagnosis of syndromic disorders and add to the phenotypic spectrum of CFCS.